Polypyrimidine tract-binding protein

Polypyrimidine tract-binding protein, also known as PTB or hnRNP I, is an RNA-binding protein. PTB functions mainly as a splicing regulator, although it is also involved in alternative 3' end processing, mRNA stability and RNA localization.[1] Two 2020 studies have shown that depleting PTB mRNA in astrocytes can convert these astrocytes to functional neurons.[2][3] These studies also show that such a treatment can be applied to the substantia nigra of mice models of Parkinson's disease in order to convert astrocytes to dopaminergic neurons and as a consequence restore motor function in these mice.

polypyrimidine tract binding protein 1
Identifiers
SymbolPTBP1
Alt. symbolsPTB
NCBI gene5725
HGNC9583
OMIM600693
RefSeqNM_002819
UniProtP26599
Other data
LocusChr. 19 p13.3
Search for
StructuresSwiss-model
DomainsInterPro
polypyrimidine tract binding protein 2
Identifiers
SymbolPTBP2
NCBI gene58155
HGNC17662
OMIM608449
RefSeqNM_021190
UniProtQ9UKA9
Other data
LocusChr. 1 p21.3-22.1
Search for
StructuresSwiss-model
DomainsInterPro

See also

edit

References

edit
  1. ^ Valcárcel J, Gebauer F (November 1997). "Post-transcriptional regulation: the dawn of PTB". Current Biology. 7 (11): R705-8. Bibcode:1997CBio....7R.705V. doi:10.1016/S0960-9822(06)00361-7. PMID 9382788. S2CID 13820693.
  2. ^ Zhou H, Su J, Hu X, et al. (April 2020). "Glia-to-Neuron Conversion by CRISPR-CasRx Alleviates Symptoms of Neurological Disease in Mice". Cell. 181 (3): 590–603.e16. doi:10.1016/j.cell.2020.03.024. PMID 32272060. S2CID 215514410.
  3. ^ Qian H, Kang X, Hu J, et al. (June 2020). "Reversing a model of Parkinson's disease with in situ converted nigral neurons". Nature. 582 (7813): 550–556. Bibcode:2020Natur.582..550Q. doi:10.1038/s41586-020-2388-4. PMC 7521455. PMID 32581380. S2CID 220051280.
edit